EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study

Sabrina Chiloiro, Flavia Costanza, Antonella Giampietro, Amato Infante, Pier Paolo Mattogno, Flavia Angelini, Consolato Gullì, Liverana Lauretti, Mario Rigante, Alessandro Olivi, Laura De Marinis, Francesco Doglietto und 2 weitere

Frontiers in Endocrinology · 2024

DOI: 10.3389/fendo.2024.1414101 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Frontiers in Endocrinology, 2024. Verfasst von Sabrina Chiloiro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Acromegaly, Receptors, Somatotropin, Somatostatin, Human Growth Hormone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Skeletal fragility is characterized by increased frequency of vertebral fractures (VFs) in acromegaly. Several trials were conducted to identify modifiable risk factors and predictors of VFs, with limited data on the prognostic role of GH receptor (GHR) isoforms. In this study, we investigated the potential role of GHR polymorphism on the occurrence of incidental VFs (i-VFs), in patients treated with second-line medical therapies.

Methods

A longitudinal, retrospective, observational study was conducted on a cohort of 45 acromegalic patients not-responsive to first-generation somatostatin receptor ligands (fg-SRLs) and treated with GHR antagonist (Pegvisomant) or with the second-generation SRLs (Pasireotide long-acting release).

Results

Second line treatments were Pegvisomant plus fg-SRLs in 26 patients and Pasireotide LAR in 19 patients. From the group treated with fg-SRLs+Peg-V, the fl-GHR isoform was identified in 18 patients (69.2%) and the d3-GHR isoform in 8 patients (30.8%). I-VFs arose exclusively in fl-GHR isoform carriers (p=0.039). From the group treated with Pasireotide LAR, the fl-GHR isoform was identified in 11 patients (57.9%), and the d3-GHR isoform in 8 patients (42.1%). I-VFs arose exclusively in d3-GHR isoform carriers (p=0.018). Patients with fl-GHR isoform had a higher risk for i-VFs if treated with fg-SRL+Peg-V (OR: 1.6 95%IC: 1.1-2.3, p=0.04), and a lower risk if treated with Pasi-LAR (OR: 0.26 IC95%: 0.11-0.66, p=0.038).

Conclusions

Our data support a predictive role of the GHR isoforms for the occurrence of i-VFs in acromegalic patients treated with second-line drugs, tailored to the individual patient. The knowledge of the GHR polymorphism may facilitate the choice of second-line therapies, improving the therapeutic approach, in the context of personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyReceptors, SomatotropinSomatostatinHuman Growth HormoneHumansMaleFemaleMiddle AgedRetrospective StudiesPilot ProjectsAdultAgedPolymorphism, GeneticLongitudinal Studies

Stichwörter der Autor:innen

GH receptoracromegalyfractureosteopeniaosteoporosispasireotidepegvisomantsomatostatin receptor ligands

Substanzen

pegvisomantReceptors, SomatotropinSomatostatinHuman Growth Hormonepasireotide

Autor:innen und Institutionen

  • Dipartimento di Medicina Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Dipartimento di Endocrinologia, Diabetologia e Medicina Interna, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e cura a carattere scientifico (IRCCS), Rome, Italy.
  • Dipartimento di Diagnostica per Immagini e radioterapia oncologica, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e cura a carattere scientifico (IRCCS), Rome, Italy.
  • Dipartimento di Neurochirugia, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e cura a carattere scientifico (IRCCS), Rome, Italy.
  • Dipartimento di Science dell'invecchiamento, neuroscienze, delle scienze del capo-collo, ed ortopediche, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Unità di Otorinologingoiatria, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e cura a carattere scientifico (IRCCS), Rome, Italy.

Förderung

  • Pfizer

Zitieren

APA

Chiloiro, S., Costanza, F., Giampietro, A., Infante, A., Mattogno, P. P., Angelini, F., Gullì, C., Lauretti, L., Rigante, M., Olivi, A., De Marinis, L., Doglietto, F., Bianchi, A., & Pontecorvi, A. (2024). GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1414101

Vancouver

Chiloiro S, Costanza F, Giampietro A, Infante A, Mattogno PP, Angelini F, et al. GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study. Frontiers in Endocrinology. 2024. doi:10.3389/fendo.2024.1414101

BibTeX
@article{Chiloiro2024,
  author = {Chiloiro, Sabrina and Costanza, Flavia and Giampietro, Antonella and Infante, Amato and Mattogno, Pier Paolo and Angelini, Flavia and Gullì, Consolato and Lauretti, Liverana and Rigante, Mario and Olivi, Alessandro and De Marinis, Laura and Doglietto, Francesco and Bianchi, Antonio and Pontecorvi, Alfredo},
  title = {GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study},
  journal = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1414101}
}
Kostenlos starten →